SCHEMBL10169327

SCHEMBL10169327

CC(C)c1cccc(N(C)S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H3 Q13133 2/20 0.53
CA12 O43570 1/20 0.53
CA9 Q16790 1/20 0.53
HSD17B1 P14061 3/20 0.49
HSD17B2 P37059 3/20 0.49
HTT P42858 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NR1I2 O75469 1/20 0.47
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 1/20 0.46
F2 P00734 2/20 0.45
PGR P06401 2/20 0.45
TSHR P16473 1/20 0.44
KAT6A Q92794 1/20 0.44
ATM Q13315 1/20 0.43
NR1H2 P55055 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10169504 0.91 HSD17B1 (0.59) NR1H3CA12CA9HSD17B1HSD17B2
SCHEMBL18085884 0.91 LMNA (0.55) CA12CA9HSD17B1HSD17B2HTT
SCHEMBL10169508 0.87 FFAR1 (0.50) NR1H3CA12CA9HSD17B1HSD17B2
SCHEMBL10169507 0.85 HSD17B1 (0.48) NR1H3HSD17B1HSD17B2HTTL3MBTL1
SCHEMBL10169506 0.85 NPC1 (0.60) CA12CA9HSD17B1HSD17B2HTT
SCHEMBL10169398 0.83 CYP11B1 (0.47) NR1H3HSD17B1HSD17B2L3MBTL1F2
SCHEMBL10169213 0.80 ALDH1A1 (0.48) CA9HTTL3MBTL1LMNASMN1; SMN2
SCHEMBL812702 0.79 CA12 (0.78) NR1H3CA12CA9HTTL3MBTL1
SCHEMBL10212263 0.79 CA12 (0.67) NR1H3CA12CA9HSD17B1HSD17B2
SCHEMBL10169505 0.79 HTR7 (0.46) CA9HTTL3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 WO disclosed
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT NR1H3 2135/4885CA12 4838/4885CA9 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.